

AUTHOR INDEX FOR VOLUME 36

A

- Abidi, T. F., *see* Mermelstein, F. H., 848
 Abramson, S. N., Radic, Z., Manker, D., Faulkner, D. J., and Taylor, P. Onchidal: A naturally occurring irreversible inhibitor of acetylcholinesterase with a novel mechanism of action, 349
 Abrass, I. B., *see* Allen, J. M., 248
 Aizu, E., *see* Nakadate, T., 917
 Akiyama, S.-I., Yoshimura, A., Kikuchi, H., Sumizawa, T., Kuwano, M., and Tahara, Y. Synthetic isoprenoid photoaffinity labeling of P-glycoprotein specific to multidrug-resistant cells, 730
 Alderson, B., *see* Palade, P., 664, 673
 Allen, J. M., Abrass, I. B., and Palmiter, R. D. β_2 -adrenergic receptor regulation after transfection into a cell line deficient in the cAMP-dependent protein kinase, 248
 Andreu, J. M., *see* Mollinedo, F., 547
 Aoyama, T., *see* Yamano, S., 83
 Aronstam, R. S., *see* Spivak, C. E., 177
 Artman, M., Robertson, D. W., Mahony, L., and Thompson, W. J. Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3 H]LY186126 in ventricular myocardium, 302
 Ashby, B. Model of prostaglandin-regulated cyclic AMP metabolism in intact platelets: Examination of time-dependent effects on adenylate cyclase and phosphodiesterase activities, 866

B

- Bailey, J. C., *see* Hodges, T. D., 72
 Barber, R., Goka, T. J., and Butcher, R. W. Growth of S49 cells in low concentrations of β -adrenergic agonists causes desensitization, 459
 Barber, R., *see* Stickle, D., 437
 Barrett, R. W., Steffey, M. E., and Wolfram, C. A. W. Type-A cholecystokinin binding sites in cow brain: Characterization using (-)-[3 H]L364718 membrane binding assays, 285
 Barrett, R. W., *see* Lin, C. W., 881
 Batist, G., Torres-Garcia, S., Demuys, J.-M., Greene, D., Lehnert, S., Rochon, M., and Panasci, L. Enhanced DNA cross-link removal: The apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line, 224
 Baumgold, J., and Drobnick, A. An agonist that is selective for adenylate cyclase-coupled muscarinic receptors, 465
 Beavo, J. A., *see* Gillespie, P. G., 773
 Bernstein, G., Haga, T., and Ichiyama, A. Effect of the lipid environment on the differential affinity of purified cerebral and atrial muscarinic acetylcholine receptors for pirenzepine, 601
 Bhatnagar, A., Liu, S., Das, B., and Srivastava, S. K. Involvement of sulfhydryl residues in aldose reductase-inhibitor interaction, 825
 Bijsterbosch, M. K., Ziere, G. J., and Van Berkel, T. J. C. Lactosylated low density lipoprotein: A potential carrier for the site-specific delivery of drugs to Kupffer cells, 484
 Birdsall, N. J. M., *see* Poyner, D. R., 420
 Blättler, W. A., *see* Goldmacher, V. S., 818
 Blaustein, M. P., *see* Sorensen, R. G., 689
 Bloomquist, J. R., *see* Ottea, J. A., 280
 Blumer, J. L., *see* Estus, S., 708
 Bolger, G. T., Skolnick, P., and Kempner, E. S. Radiation inactivation reveals discrete cation binding sites and modulate dihydropyridine binding sites, 327
 Bonhaus, D. W., Yeh, G.-C., Skaryak, L., and McNamara, J. O. Glycine regulation of the N-methyl-D-aspartate receptor-gated ion channel in hippocampal membranes, 273

- Booth, G., *see* Jarvie, K. R., 566
 Borchardt, R. T., *see* Hasobe, M., 490
 Bornheim, L. M., and Correia, M. A. Purification and characterization of a mouse liver cytochrome P-450 induced by cannabidiol, 377
 Bouvier, M., *see* Liggett, S. B., 641
 Boyer, J. L., and Harden, T. K. Irreversible activation of phospholipase C-coupled P_{2U} -purinergic receptors by 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate, 831
 Braakman, I., Pijning, T., Verest, O., Weert, B., Meijer, D. K. F., and Groothuis, G. M. M. Vesicular uptake system for the cation lucigenin in the rat hepatocyte, 537
 Braakman, I., Verest, O., Pijning, T., Meijer, D. K. F., and Groothuis, G. M. M. Zonal distribution of the cation lucigenin in rat liver: Influence of taurocholate, 532
 Braswell, L. M., *see* Roth, S. H., 874
 Bresnick, E. H., *see* Sunahara, G. I., 239
 Breuer, E., *see* Gordon, R. K., 766
 Brodersen, R., and Robertson, A. C. Triaxone binding to human serum albumin: Competition with bilirubin, 478
 Brown, E. M., *see* Jarvie, K. R., 566
 Brown, J. H., *see* Jones, L. G., 142
 Bunzow, J. R., *see* Neve, K. A., 446
 Burch, R. M., *see* Farmer, S. G., 1
 Butcher, R. W., *see* Barber, R., 459
 Butler, G., *see* Goldmacher, V. S., 818

C

- Campbell, S. F., *see* Mason, R. P., 634
 Camus, J., *see* Waelbroeck, M., 405
 Carl, P. L., *see* Goz, B., 360
 Carlisle, R., *see* Sommadossi, J.-P., 9
 Caron, M. G., *see* Liggett, S. B., 641
 Caron, M. G., *see* Raymond, J. R., 15
 Cashman, J. R. Enantioselective N-oxygenation of verapamil by the hepatic flavin-containing monooxygenase, 497
 Cassel, D., *see* Humphreys, C. J., 620
 Cheng, Y.-C., *see* Liu, S.-Y., 78
 Chiang, P. K., *see* Gordon, R. K., 766
 Childers, S. R., *see* Konkoy, C. S., 627
 Chou, T.-C., *see* Lombardini, J. B., 256
 Christophe, J., *see* Waelbroeck, M., 405
 Civelli, O., *see* Neve, K. A., 446
 Clark, R. B., Friedman, J., Dixon, R. A. F., and Strader, C. D. Identification of a specific site required for rapid heterologous desensitization of the β -adrenergic receptor by cAMP-dependent protein kinase, 343
 Coleman, J. B., Gilfor, D., and Farber, J. L. Dissociation of the accumulation of single-strand breaks in DNA from the killing of cultured hepatocytes by an oxidative stress, 193
 Collier, K., *see* Nagy, L. E., 744
 Colman, P. D., *see* Moran, R. G., 736
 Commandeur, J. N. M., de Kanter, F. J. J., and Vermeulen, N. P. E. Bioactivation of the cysteine-S-conjugate and mercapturic acid of tetrafluoroethylene to acylating reactive intermediates in the rat: Dependence of activation and deactivation activities on acetyl coenzyme A availability, 654
 Cools, M., *see* Hasobe, M., 490
 Coon, M. J., *see* Porter, T. D., 61
 Correia, M. A., *see* Bornheim, L. M., 377
 Costa, E., *see* Danysz, W., 912

- Costa, E., *see* Manev, H., 106
 Coutsogeorgopoulos, C., *see* Kalpaxis, D. L., 615
 Cowan, K. H., *see* Moscow, J. A., 22
 Cragoe, E. J., Jr., *see* Palaty, V., 296
 Creese, I., *see* Riva, M. A., 201, 218
 Curtis, C., *see* Poyner, D. R., 420

D

- Daly, J. W., *see* Gusovsky, F., 44
 Danenberg, K. D., and Danenberg, P. V. Activity of thymidylate synthetase and its inhibition by 5-fluorouracil in highly enzyme-overproducing cells resistant to 10-propargyl-5,8-dideazafolate, 219
 Danenberg, K. D., *see* Denenberg, P. V., 219
 Daniell, L. C., and Harris, R. A. Effect of anesthetics on calcium stores and membrane order of brain microsomes, 471
 Danysz, W., Fadda, E., Wroblewski, J. T., and Costa, E. Different modes of action of 3-amino-1-hydroxy-2-pyrrolidone (HA-966) and 7-chlorokynurenic acid in the modulation of *N*-methyl-D-aspartate-sensitive glutamate receptors, 912
 Das, B., *see* Bhatnagar, A., 825
 Davies, M. F., *see* Villar, H. O., 589
 Dean, J. H., *see* Pallardy, M. J., 128
 Debnath, A. K., *see* Shusterman, A. J., 939
 De Carvalho, M. S., *see* Glaser, K. B., 782
 De Clercq, E., *see* Hasobe, M., 490
 de Kanter, F. J. J., *see* Commandeur, J. N. M., 654
 Demuys, J.-M., *see* Batist, G., 224
 Dettbarn, C., *see* Palade, P., 664, 673
 Diamond, I., *see* Nagy, L. E., 744
 Didsbury, J., *see* Longabaugh, 681
 Dingledine, R., *see* Kleckner, N. W., 430
 Dingledine, R., *see* McBain, C. J., 556
 Dixon, R. A. F., *see* Strader, C. D., 343
 Drobnick, A., *see* Baumgold, J., 465
 Duff, H. J., *see* Hill, R. J., 150

E

- Eling, T., *see* Thompson, D., 809
 Escande, D., *see* Thuringer, D., 897
 Estus, S., and Blumer, J. L. Role of microtubule assembly in phenytoin teratogenic action in the sea urchin (*Arbacia punctulata*) embryo, 708
 Evelieigh, P., *see* Poyner, D. R., 420

F

- Fadda, E., *see* Danysz, W., 912
 Fahey, M. A., *see* Madras, B. K., 518
 Falany, C. N., *see* Heroux, J. A., 29
 Farber, J. L., *see* Coleman, J. B., 193
 Fargin, A., *see* Raymond, J. R., 15
 Farmer, S. G., Burch, R. M., Meeker, S. A., and Wilkins, D. E. Evidence for a pulmonary B₃ bradykinin receptor, 1
 Faulkner, D. J., *see* Abramson, S. N., 349
 Faulkner, D. J., *see* Glaser, K. B., 782
 Favaron, M., *see* Manev, H., 106
 Fleming, J. W., *see* Hodges, T. D., 72
 Forman, S. A., *see* Roth, S. H., 874
 Foxwell, B. M. J., Mackie, A., Ling, V., and Ryffel, B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein, 543
 Fraser, C. M., Wang, C.-D., Robinson, D. A., Gocayne, J. D., and Venter, J. C. Site-directed mutagenesis of m₁ muscarinic acetylcholine receptors: Conserved aspartic acids play important roles in receptor function, 840
 Fridland, A., *see* Johnson, M. A., 291
 Friedman, J., *see* Clark R. B., 343

- Fronczek, F. R., *see* Shusterman, A. J., 939
 Funae, Y., *see* Yamazoe, Y., 716

G

- Gati, W. P., and Paterson, A. R. P. Interaction of [³H]diazepam at nucleoside transporter-associated bindings sites on S49 mouse lymphoma cells, 134
 Gelboin, H. V., *see* Yamano, S., 83
 Gierschik, P., *see* McLeish, K. R., 384
 Gilfor, D., *see* Coleman, J. B., 193
 Gillespie, P. G., and Beavo, J. A. Inhibition and stimulation of photo-receptor phosphodiesterases by dipyrindamole and M&B 22,948, 773
 Glaser, K. B., De Carvalho, M. S., Jacobs, R. S., Kernan, M. R., and Faulkner, D. J. Manoalide: Structure-activity studies and definition of the pharmacocore for phospholipase A₂ inactivation, 782
 Glover, E., *see* Poland, A., 113, 121
 Gocayne, J. D., *see* Fraser, C. M., 840
 Goka, T. J., *see* Barber, R., 459
 Goldmacher, V. S., Blättler, W. A., Lambert, J. M., Butler, G., and Stewart, J. Cytotoxicity of gelonin conjugated to targeting molecules: Effects of weak amines, monensin, adenovirus, and adenoviral capsid proteins penton, hexon, and fiber, 818
 Goldstein, A., and Naidu, A. Multiple opioid receptors: Ligand selectivity profiles and binding site signatures, 265
 Gonzalez, F. J., *see* Kronbach, T., 89
 Gonzalez, F. J., *see* Yamano, S., 83
 Gordon, A. S., *see* Nagy, L. E., 744
 Gordon, R. K., Breuer, E., Padilla, F. N., Smejkal, R. M., and Chiang, P. K. Distance geometry of a α -substituted 2,2-diphenylpropionate antimuscarinics, 766
 Goz, B., Carl, P. L., and Tlsty, T. D. 1- β -D-arabinofuranosylcytosine enhancement of resistance of several antieoplastic drugs in mammalian tissue culture cells, 360
 Green, R. D., *see* Leung, E., 412
 Greene, A. C., *see* Shusterman, A. J., 939
 Greene, D., *see* Batist, G., 224
 Groothuis, G. M. M., *see* Braakman, I., 532, 537
 Guidotti, A., *see* Manev, H., 106
 Gundersen, C. B., *see* Umbach, J. A., 582
 Gusovsky, F., Yasumoto, T., and Daly, J. W. Calcium-dependent effects of maitotoxin on phosphoinositide breakdown and on cyclic AMP accumulation in PC12 and NCB-20 cells, 44

H

- Haga, T., *see* Bernstein, G., 601
 Hansch, C., *see* Shusterman, A. J., 939
 Hansen, C. A., *see* Joseph, S. K., 391
 Harden, T. K., *see* Boyer, J. L., 831
 Hardwick, J. P., *see* Yamano, S., 83
 Harris, R. A., *see* Daniell, L. C., 471
 Harrison, J. H., Jr., Hoty, D. G., and Lazo, J. S. Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice, 231
 Haruna, M., *see* Liu, S.-Y., 78
 Hashimoto, K., *see* Tsujimoto, G., 166
 Hasobe, M., McKee, J. G., Ishii, H., Cools, M., Borchardt, R. T., and De Clercq, E. Elucidation of the mechanism by which homocystein potentiates the anti-vaccinia virus effects of the *S*-adenosylhomocysteine hydrolase inhibitor 9-(*trans*-2',*trans*-3'-dihydroxycyclopent-4'-enyl)-ad enine, 490
 Hausdorff, W. P., *see* Liggett, S. B., 641
 Henningsen, R. A., *see* Neve, K. A., 446
 Herbette, L. G., *see* Mason, R. P., 634
 Heroux, J. A., Falany, C. N., and Roth, J. A. Immunological characterization of human phenol sulfotransferase, 29
 Higham, D. P., *see* Nicholson, J. K., 398

- Hill, R. J., Duff, H. J., and Sheldon, R. S. Class I antiarrhythmic drug receptor: Biochemical evidence for state-dependent interaction with quinidine and lidocaine, 150
- Himes, R. H., *see* Singer, W. D., 366
- Hinton, D. E., *see* Stegeman, J. J., 723
- Hodges, T. D., Bailey, J. C., Fleming, J. W., and Kovacs, R. J. Selective parasympathectomy increases the quantity of inhibitory guanine nucleotide-binding proteins in canine cardiac ventricle, 72
- Holladay, M. W., *see* Lin, C. W., 881
- Horn, G. W., *see* Shusterman, A. J., 939
- Hortin, G. L., *see* Rens-Domiano, S., 647
- House, R. V., *see* Pallardy, M. J., 128
- Hoyt, D. G., *see* Harrison, J. H., Jr., 231
- Hsiang, Y.-H., Jiang, J. B., and Liu, L. F. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs, 371
- Hulme, E. C., *see* Poyner, D. R., 420
- Humphreys, C. J., Cassel, D., and Rudnick, G. 2-iodoimipramine, a novel ligand for the serotonin transporter, 620
- Hwang, B.-D., *see* Liu, S.-Y., 78
- I**
- Ichiyama, A., *see* Berstein, G., 601
- Imakura, Y., *see* Liu, S.-Y., 78
- Imaoka, S., *see* Yamazoe, Y., 716
- Insel, P. A., *see* Weiss, B. A., 317
- Ishii, H., *see* Hasobe, M., 490
- Itzhak, Y. Multiple affinity binding states of the σ receptor: Effect of GTP-binding protein-modifying agents, 512
- J**
- Jacobs, R. S., *see* Glaser, K. B., 782
- Jacobson, A. E., *see* Rothman, R. B., 887
- Jakobs, K. H., *see* McLeish, K. R., 384
- Janssen, P. A. J., *see* Pauwels, P. J., 525
- Jarvie, K. R., Booth, G., Brown, E. M., and Niznik, H. B. Glycoprotein nature of dopamine D1 receptors in the brain and parathyroid gland, 566
- Jiang, J. B., *see* Hsiang, Y.-H., 371
- Johnson, K. M., *see* Sacca, A. I., 836
- Johnson, M. A., and Fridland, A. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells, 291
- Jones, L. G., McDonough, P. M., and Brown, J. H. Thrombin and trypsin act at the same site to stimulate phosphoinositide hydrolysis and calcium mobilization, 142
- Jones, T. R., *see* Moran, R. G., 736
- Jordan, M. A., *see* Singer, W. D., 366
- Joseph, S. K., Hansen, C. A., and Williamson, J. R. Inositol tetrakisphosphate mobilized calcium from cerebellum microsomes, 391
- K**
- Kalpaxis, D. L., and Coutsoygeorgopoulos, C. Type of inhibition of peptide bond formation by chloramphenicol depends on the temperature and the concentration of ammonium ions, 615
- Kato, R., *see* Nakadate, T., 917
- Kato, R., *see* Yamazoe, Y., 716
- Kaufman, R., Roger, G. A., Fehlmann, C., and Parsons, S. M. Fractional vesamical receptor occupancy and acetylcholine active transport inhibition in synaptic vesicles, 452
- Kellar, K. J., *see* Stockmeier, C. A., 903
- Kempner, E. S., *see* Bolger, G. T., 327
- Kende, A., *see* Poland, A., 121
- Kernan, M. R., *see* Glaser, K. B., 782
- Kerwin, J. F., Jr., *see* Lin, C. W., 881
- Khani, S. C., *see* Porter, T. D., 61
- Kikuchi, H., *see* Akiyama, S.-I., 730
- Kleckner, N. W., and Dingledine, R. Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on *N*-methyl-D-aspartate receptors, 430
- Kleckner, N. W., *see* McBain, C. J., 556
- Knowlton, R., *see* Roskoski, R., Jr., 925
- Konkoy, C. S., and Childers, S. R. Dynorphin-selective inhibition of adenylyl cyclase in guinea pig cerebellum membranes, 627
- Konno, K., *see* Yokota, T., 312
- Kovacs, R. J., *see* Hodges, T. D., 72
- Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., and Meyer, U. A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIA4, 89
- Krueger, B. K., *see* O'Leary, 789
- Kumagai, M., *see* Yokota, T., 312
- Kuwano, M., *see* Akiyama, S.-I., 730
- L**
- Lambert, J. M., *see* Goldmacher, V. S., 818
- Laskin, J. D., *see* Mermelstein, F. H., 848
- Lazo, J. S., *see* Harrison, J. H., Jr., 231
- Lee, K.-H., *see* Liu, S.-Y., 78
- Lee, W., and Wolfe, B. B. Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration, 749
- Lefkowitz, R. J., *see* Liggett, S. B., 641
- Lefkowitz, R. L., *see* Raymond, J. R., 15
- Lehnert, S., *see* Batist, G., 224
- Leung, E., and Green, R. D. Density gradient profiles of A_1 adenosine receptors labeled by agonist and antagonist radioligands before and after detergent solubilization, 412
- Leysen, J. E., *see* Pauwels, P. J., 525
- Liebowitz, S. M., *see* Lombardini, J. B., 256
- Liggett, S. B., Bouvier, M., Hausdorff, W. P., O'Dowd, B., Caron, M. G., and Lefkowitz, R. J. Altered patterns of agonist-stimulated cAMP accumulation in cells expressing mutant β_2 -adrenergic receptors lacking phosphorylation sites, 641
- Lin, C. W., Holladay, M. W., Barrett, R. W., Wolfram, C. A. W., Miller, T. R., Witte, D., Kerwin, J. F., Jr., Wagenaar, F., and Nadzan, A. M. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: Studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33), 881
- Ling, V., *see* Foxwell, B. M. J., 543
- Liu, L. F., *see* Hsiang, Y.-H., 371
- Liu, S., *see* Bhatnagar, A., 825
- Liu, S.-Y., Hwang, B.-D., Haruna, M., Imakura, Y., Lee, K.-H., and Cheng, Y.-C. Podophyllotoxin analogs: Effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants, 78
- Loew, G. H., *see* Villar, H. O., 589
- Lohse, M. J., *see* Raymond, J. R., 15
- Lombardini, J. B., Liebowitz, S. M., and Chou, T.-C. Analogues of taurine as stimulators and inhibitors of ATP-dependent calcium ion uptake in rat retina: Combination kinetics, 256
- Longabaugh, J. P., Didsbury, J., Spiegel, A., and Stiles, G. L. Modification of the rat adipocyte A_1 adenosine receptor-adenylate cyclase system during chronic exposure to an A_1 adenosine receptor agonist: Alterations in the quantity of $G_{\alpha s}$ and $G_{\alpha i}$ are not associated with changes in their mRNAs, 681
- Loo, P. S., *see* Sills, M. A., 160
- Lopez, L., *see* Nagy, L. E., 744
- Lu, X.-L., and Yang, S. K. Metabolism of prazepam by rat liver microsomes: Stereoselective formation and *N*-dealkylation of 3-hydroxyprazepam, 932
- Lucier, G. W., *see* Sunahara, G. I., 239
- M**
- Machida, H., *see* Yokota, T., 312
- Mackie, A., *see* Foxwell, B. M. J., 543
- Madras, B. K., Spealman, R. D., Fahey, M. A., Neumeyer, J. L., Saha,

- J. K., and Milius, R. A. Cocaine receptors labeled by [³H]2 β -carbomethoxy-3 β -(4-fluorophenyl)tropane, 518
- Mahony, L., *see* Artman, M., 302
- Manev, H., Favaron, M., Guidotti, A., and Costa, E. Delayed increase of Ca²⁺ influx elicited by glutamate: Role in neuronal death, 106
- Manker, D., *see* Abramson, S. N., 349
- Marka, G. S.; *see* McCluskey, S. A., 608
- Mason, R. P., Campbell, S. F., Wang, S.-D., and Herbette, L. G. Comparison of location and binding for the positively charged 1, 4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes, 634
- Mathys, D., *see* Kronbach, T., 89
- McBain, C. J., Kleckner, N. W., Wyrick, S., and Dingledine, R. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in *Xenopus* oocytes, 556
- McBride, O. W., *see* Yamano, S., 83
- McCluskey, S. A., Whitney, R. A., and Marks, G. S. Evidence for the stereoselective inhibition of chick embryo hepatic ferrochelatase by N-alkylated porphyrins, 608
- McCoy, Z., *see* Sunahara, G. I., 239
- McDonough, P. M., *see* Jones, L. G., 142
- McKee, J. G., *see* Hasobe, M., 490
- McLeish, K. R., Gierschik, P., and Jakobs, K. H. Desensitization uncouples the formyl peptide receptor-guanine nucleotide-binding protein interaction in HL60 cells, 384
- McNamara, J. O., *see* Bonhaus, D. W., 273
- Meeker, S. A., *see* Farmer, S. G., 1
- Meijer, D. K. F., *see* Braakman, I., 532, 537
- Mermelstein, F. H., Abidi, T. F., and Laskin, J. D. Inhibition of epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid cells following psoralen/ultraviolet light treatment, 848
- Meyer, U. A., *see* Kronbach, T., 89
- Milius, R. A., *see* Madras, B. K., 518
- Miller, K. W., *see* Roth, S. H., 874
- Miller, L. G., Roy, R. B., and Weill, C. L. Chronic clonazepam administration decreases γ -aminobutyric acid_A receptor function in cultured cortical neurons, 796
- Miller, L. J., *see* Otterness, D. M., 856
- Miller, M. R., *see* Stegeman, J. J., 723
- Miller, R. J., *see* Reynolds, I. J., 758
- Miller, T. R., *see* Lin, C. W., 881
- Molinoff, P. B., *see* Williams, K., 575
- Mollinedo, F., Nieto, J. M., and Andreu, J. M. Cytoplasmic microtubules in human neutrophil degranulation: Reversible inhibition by the colchicine analogue 2-methoxy-5-(2',3',4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one, 547
- Monn, J. A., *see* Rothman, R. B., 887
- Moran, R. G., Colman, P. D., and Jones, T. R. Relative substrate activities of structurally related pteridine, quinazoline, and pyrimidine analogs for mouse liver folylpolyglutamate synthetase, 736
- Morgan, E. T. Suppression of constitutive cytochrome P-450 gene expression in livers of rats undergoing an acute phase response to endotoxin, 699
- Mori, S., *see* Yokota, T., 312
- Moscow, J. A., Townsend, A. J., and Cowan, K. H. Elevation of π class glutathione S-transferase activity in human breast cancer cells by transfection of the GST π gene and its effect on sensitivity to toxins, 22
- Murayama, N., *see* Yamazoe, Y., 716
- N**
- Nadzan, A. M., *see* Lin, C. W., 881
- Nagy, L. E., Diamond, I., Collier, K., Lopez, L., Ullman, B., and Gordon, A. S. Adenosine is required for ethanol-induced heterologous desensitization, 744
- Naidu, A., *see* Goldstein, A., 265
- Nakadate, T., Yamamoto, S., Aizu, E., Nishikawa, K., and Kato, R. H-7, a protein kinase C inhibitor, inhibits phorbol ester-caused ornithine decarboxylase induction but fails to inhibit phorbol ester-caused suppression of epidermal growth factor binding in primary cultured mouse epidermal cells, 917
- Nathanson, J. A. Development of a photoaffinity ligand for octopamine receptors, 34
- Nelson, K. G., *see* Sunahara, G. I., 239
- Neumeyer, J. L., *see* Madras, B. K., 518
- Neve, K. A., Henningsen, R. A., Bunzow, J. R., and Civelli, O. Functional characterization of a rat dopamine D-2-receptor cDNA expressed in a mammalian cell line, 446
- Nicholson, J. K., Higham, D. P., Timbrell, J. A., and Sadler, P. J. Quantitative high resolution ¹H NMR urinalysis studies on the biochemical effects of cadmium in the rat, 398
- Nieto, J. M., *see* Mollinedo, F., 547
- Nishikawa, K., *see* Nakadate, T., 917
- Niznik, H. B., *see* Jarvie, K. R., 566
- O**
- O'Brien, C. A., and Ward, N. E. ATP-sensitive binding of melittin to the catalytic domain of protein kinase C, 355
- O'Dowd, B., *see* Liggett, S. B., 641
- O'Leary, M. E., and Krueger, B. K. Batrachotoxin and α -scorpion toxin stabilize the open state of single voltage-gated sodium channels, 789
- Otero, A. S., *see* Palade, P., 664
- Ottea, J. A., Payne, G. T., Bloomquist, J. R., and Soderlund, D. M. Activation of sodium channels and inhibition of [³H]batrachotoxinin A-20- α -benzoate binding by an N-alkylamide neurotoxin, 280
- Otterness, D. M., Powers, S. P., Miller, L. J., and Weinshilboum, R. M. Human liver thermostable phenol sulfotransferase: Photoaffinity labeling with 2-iodo-4-azidophenol, 856
- Ozawa, H., and Rasenick, M. M. Coupling of the stimulatory GTP-binding protein G_s to rat synaptic membrane adenylate cyclase is enhanced subsequent to chronic antidepressant treatment, 803
- P**
- Padilla, F. N., *see* Gordon, R. K., 766
- Palade, P., Dettbarn, C., Alderson, B., and Volpe, P. Pharmacologic differentiation between inositol-1,4,5-trisphosphate-induced Ca²⁺ release and Ca²⁺- or caffeine-induced Ca²⁺ release from intracellular membrane systems, 673
- Palade, P., Dettbarn, C., Volpe, P., Alderson, B., and Otero, A. S. Direct inhibition of inositol-1,4,5-trisphosphate-induced Ca²⁺ release from brain microsomes by K⁺ channel blockers, 664
- Palaty, V., and Cragoe, E. J., Jr. Inhibition of monamine oxidase by analogues of amiloride, 296
- Palmiter, R. D., *see* Allen, J. M., 248
- Panasci, L., *see* Batist, G., 224
- Parsons, S. M., *see* Rogers, G. A., 333
- Paterson, A. R. P., *see* Gati, W. P., 134
- Pauwels, P. J., van Assouw, H. P., Leysen, J. E., and Janssen, P. A. J. Ca²⁺-mediated neuronal death in rat brain neuronal cultures by veratridine: Protection by flunarizine, 525
- Payne, G. T., *see* Ottea, J. A., 280
- Pedder, E. K., *see* Poyner, D. R., 420
- Peroutka, S. J., *see* Schmidt, A. W., 505
- Pijning, T., *see* Braakman, I., 532, 537
- Plagemann, P. G. W., and Woffendin, C. Permeation and salvage of dideoxyadenosine in mammalian cells, 185
- Poland, A., Teitelbaum, P., and Glover, E. [¹²⁵I]2-iodo-3,7,8-trichlorodibenzo-p-dioxin-binding species in mouse liver induced by agonists for the Ah receptor: Characterization and identification, 113
- Poland, A., Teitelbaum, P., Glover, E., and Kende, A. Stimulation of *In Vivo* hepatic uptake and *In Vitro* hepatic binding of [¹²⁵I]2-iodo-3,7,8-trichlorodibenzo-p-dioxin by the administration of agonists

- for the Ah receptor, 121
- Polgar, W., *see* Villar, H. O., 589
- Pollardy, M. J., House, R. V., and Dean, J. H. Molecular mechanism of 7,12-dimethylbenz[a]anthracene-induced immunosuppression: Evidence for action via the interleukin-2 pathway, 128
- Porter, T. D., Khani, S. C., and Coon, M. J. Induction and tissue-specific expression of rabbit cytochrome P450IIE1 and IIE2 genes, 61
- Powers, S. P., *see* Otterness, D. M., 856
- Poyner, D. R., Birdsall, N. J. M., Curtis, C., Eveleigh, P., Hulme, E. C., Pedder, E. K., and Wheatley, M. Binding and hydrodynamic properties of muscarinic receptor subtypes solubilized in 3-(3-cholamidopropyl)dimethylammonio-2-hydroxy-1-propanesulfonate, 420
- Q**
- Quattrochi, L. C., and Tukey, R. H. The human cytochrome CYP1A2 gene contains regulatory elements responsive to 3-methylcholanthrene, 66
- R**
- Radic, Z., *see* Abramson, S. N., 349
- Rasenick, M. M., *see* Ozawa, H., 803
- Raymond, J. R., Fargin, A., Lohse, M. J., Regan, J. W., Senogles, S. E., Lefkowitz, R. J., and Caron, M. C. Identification of the ligand-binding subunit of the human 5-hydroxytryptamine_{1A} receptor with *N*-(*p*-azido-*m*-[¹²⁵I]iodophenethyl)piperone, a high affinity radioiodinated photoaffinity probe, 15
- Regan, J. W., *see* Raymond, J. R., 15
- Reid, A. A., *see* Rothman, R. B., 887
- Rens-Domiano, S., Hortin, G. L., and Roth, J. A. Sulfation of *tert*-butoxycarbonylcholecystokinin and other peptides by rat liver tyrosylprotein sulfotransferase, 647
- Reynolds, I. J., and Miller, R. J. Ifenprodil is a novel type of *N*-methyl-D-aspartate receptor antagonist: Interaction with polyamines, 758
- Rice, K. C., *see* Rothman, R. B., 887
- Riley, L. A., Waguepack, M. A., and Denney, R. M. Characterization and quantitation of monoamine oxidases A and B in mitochondria from human placenta, 54
- Ring, B. J., *see* Wrighton, S. A., 97
- Riva, M. A., and Creese, I. Comparison of two putatively selective radioligands for labeling central nervous system β -adrenergic receptors: Inadequacy of [³H]dihydroalprenolol, 201
- Riva, M. A., and Creese, I. Reevaluation of the regulation of β -adrenergic receptor binding by desipramine treatment, 218
- Robertson, A., *see* Brodersen, R., 478
- Robertson, D. W., *see* Artman, M., 302
- Robinson, D. A., *see* Fraser, C. M., 840
- Rochon, M., *see* Batist, G., 224
- Rogers, G. A., and Parsons, S. M. Inhibition of acetylcholine storage by acetylcholine analogs *In Vitro*, 333
- Romano, C., *see* Williams, K., 575
- Roskoski, L. M., *see* Roskoski, R., Jr., 925
- Roskoski, R., Jr., White, L., Knowlton, R., and Roskoski, L. M. Regulation of tyrosine hydroxylase activity in rat PC12 cells by neuropeptides of the secretin family, 925
- Roth, J. A., *see* Heroux, J. A., 29
- Roth, J. A., *see* Rens-Domiano, S., 647
- Roth, S. H., Forman, S. A., Braswell, L. M., and Miller, K. W. Actions of pentobarbital enantiomers on nicotinic cholinergic receptors, 874
- Rothman, R. B., Reid, A. A., Monn, J. A., Jacobson, A. E., and Rice, K. C. The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: Evidence for *N*-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites, 887
- Roy, R. B., *see* Miller, L. G., 796

- Rudnick, G., *see* Humphreys, C. J., 620
- Ryffel, B., *see* Foxwell, B. M. J., 543

S

- Sacaan, A. I., and Johnson, K. M. Spermine enhances binding to the glycine site associated with the *N*-methyl-D-aspartate receptor complex, 836
- Sadler, P. J., *see* Nicholson, J. K., 398
- Saha, J. K., *see* Madras, B. K., 518
- Sanchez, E. R., *see* Sunahara, G. I., 239
- Schmidt, A. W., and Peroutka, S. J. Three-dimensional steric molecular modeling of the 5-hydroxytryptamine, receptor pharmacophore, 505
- Senogles, S. E., *see* Raymond, J. R., 15
- Sheldon, R. S., *see* Hill, R. J., 150
- Shigeta, S., *see* Yokota, T., 312
- Shimada, M., *see* Yamazoe, Y., 716
- Shusterman, A. J., Debnath, A. K., Hansch, C., Horn, G. W., Fronczek, F. R., Greene, A. C., and Watkins, S. F. Mutagenicity of dimethyl heteroaromatic triazenes in the Ames test: The role of hydrophobicity and electronic effects, 939
- Sills, M. A., and Loo, P. S. Tricyclic antidepressants and extromethorphan bind with high affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate, 160
- Singer, W. D., Jordan, M. A., Wilson, L., and Himes, R. H. Binding of vinblastine to stabilized microtubules, 366
- Skaryak, L., *see* Bonhaus, D. W., 273
- Skolnick, P., *see* Bolger, G. T., 327
- Slivka, S. R., *see* Weiss, B. A., 317
- Smejkal, R. M., *see* Gordon, R. K., 766
- Soderlund, D. M., *see* Ottea, J. A., 280
- Sommadossi, J.-P., Carlisle, R., and Zhou, Z. Cellular pharmacology of 3'-azido-3'-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells, 9
- Sorensen, R. G., and Blaustein, M. P. Rat brain dendrotoxin receptors associated with voltage-gated potassium channels: Dendrotoxin binding and receptor solubilization, 689
- Spealman, R. D., *see* Madras, B. K., 518
- Spiegel, A., *see* Longabaugh, 681
- Spivak, C. E., Waters, J. A., and Aronstam, R. S. Binding of semirigid nicotinic agonists to nicotinic and muscarinic receptors, 177
- Srivastava, S. K., *see* Bhatnagar, A., 825
- Steffey, M. E., *see* Barrett, R. W., 285
- Stegeman, J. J., Miller, M. R., and Hinton, D. E. Cytochrome P450IA1 induction and localization in endothelium of vertebrate (teleost) heart, 723
- Stewart, J., *see* Goldmacher, V. S., 818
- Stickle, D., and Barber, R. Evidence for the role of epinephrine binding frequency in activation of adenylate cyclase, 437
- Stiles, G. L., *see* Longabaugh, 681
- Stockmeier, C. A., and Kellar, K. J. Serotonin depletion unmasks serotonergic component of [³H]dihydroalprenolol binding in rat brain, 903
- Sumizawa, T., *see* Akiyama, S.-I., 730
- Sunahara, G. I., Lucier, G. W., McCoy, Z., Bresnick, E. H., Sanchez, E. R., and Nelson, K. G. Characterization of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-mediated decreases in dexamethasone binding to rat hepatic cytosolic glucocorticoid receptor, 239
- Suzuki, E., *see* Tsujimoto, G., 166

T

- Tahara, Y., *see* Akiyama, S.-I., 730
- Taylor, P., *see* Abramson, S. N., 349
- Teitelbaum, P., *see* Poland, A., 113, 121
- Thompson, D., and Eling, T. Mechanism of inhibition of prostaglandin H synthase by eugenol and other phenolic peroxidase substrates, 809

- Thompson, W. J., *see* Artman, M., 302
 Thuringer, D., and Escande, D. Apparent competition between ATP and the potassium channel opener RP 49356 on ATP-sensitive K⁺ channels of cardiac myocytes, 897
 Timbrell, J. A., *see* Nicholson, J. K., 398
 Tlsty, T. D., *see* Goz, B., 360
 Toll, L., *see* Villar, H. O., 589
 Torres-Garcia, S., *see* Batist, G., 224
 Townsend, A. J., *see* Moscow, J. A., 22
 Tsujimoto, G., Tsujimoto, A., Suzuki, E., and Hashimoto, K. Glycogen phosphorylase activation by two different α_1 -adrenergic receptor subtypes: Methoxamine selectively stimulates a putative α_1 -adrenergic receptor subtype (α_{1A}) that couples with Ca²⁺ influx, 166
 Tsujimoto, A., *see* Tsujimoto, G., 166
 Tukey, R. H., *see* Quattrochi, L. C., 66

U

- Ullman, B., *see* Nagy, L. E., 744
 Umbach, J. A., and Gundersen, C. B. Mercuric ions are potent noncompetitive antagonists of human brain kainate receptors expressed in *Xenopus* oocytes, 582
 Umeno, M., *see* Kronbach, T., 89
 Uyeno, E. T., *see* Villar, H. O., 589

V

- van Assouw, H. P., *see* Pauwels, P. J., 525
 Van Berkel, T. J. C., *see* Bijsterbosch, M. K., 484
 Vandenbranden, M., *see* Wrighton, S. A., 97
 Venter, J. C., *see* Fraser, C. M., 840
 Verest, O., *see* Braakman, I., 532, 537
 Vermeulen, N. P. E., *see* Commandeur, J. N. M., 654
 Villar, H. O., Uyeno, E. T., Toll, L., Polgar, W., Davies, M. F., and Loew, G. H. Molecular determinants of benzodiazepine receptor affinities and anticonvulsant activities, 589
 Volpe, P., *see* Palade, P., 664, 673

W

- Waelbroeck, M., Camus, J., and Christophe, J. Determination of the association and dissociation rate constants of muscarinic antagonists on rat pancreas: Rank order of potency varies with time, 405
 Wagenaar, F., *see* Lin, C. W., 881
 Wang, C.-D., *see* Fraser, C. M., 840
 Wang, S.-D., *see* Mason, R. P., 634
 Ward, N. E., *see* O'Brien, C. A., 355
 Watanabe, Y., *see* Yokota, T., 312
 Waters, J. A., *see* Spivak, C. E., 177
 Watkins, P. B., *see* Wrighton, S. A., 97
 Watkins, S. F., *see* Shusterman, A. J., 939
 Weert, B., *see* Braakman, I., 537

- Weill, C. L., *see* Miller, L. G., 796
 Weinshilboum, R. M., *see* Otterness, D. M., 856
 Weiss, B. A., Slivka, S. R., and Insel, P. A. Defining the role of protein kinase C in epinephrine- and bradykinin-stimulated arachidonic acid metabolism in madin-darby canine kidney cells, 317
 Wheatley, M., *see* Poyner, D. R., 420
 White, L., *see* Roskoski, R., Jr., 925
 Whitney, R. A., *see* McCluskey, S. A., 608
 Wilkins, D. E., *see* Farmer, S. G., 1
 Williams, K., Romano, C., and Molinoff, P. B. Effects of polyamines on the binding of [³H]MK-801 to the N-methyl-D-aspartate receptor: Pharmacological evidence for the existence of a polyamine recognition site, 575
 Williamson, J. R., *see* Joseph, S. K., 391
 Wilson, L., *see* Singer, W. D., 366
 Witte, D., *see* Lin, C. W., 881
 Woffendin, C., *see* Plagemann, P. G. W., 185
 Wolfe, B. B., *see* Lee, W., 749
 Wolfram, C. A. W., *see* Barrett, R. W., 285
 Wolfram, C. A. W., *see* Lin, C. W., 881
 Wrighton, S. A., Ring, B. J., Watkins, P. B., and Vandenbranden, M. Identification of a polymorphically expressed member of the human cytochrome P-450III family, 97
 Wroblewski, J. T., *see* Danysz, W., 912
 Wyrick, S., *see* McBain, C. J., 556

Y

- Yamamoto, S., *see* Nakadate, T., 917
 Yamano, S., Aoyama, T., McBride, O. W., Hardwick, J. P., Gelboin, H. V., and Gonzalez, F. J. Human NADPH-P450 oxidoreductase: Complementary DNA cloning, sequence and vaccinia virus-mediated expression and localization of the CYPOR gene to chromosome 7, 83
 Yamazoe, Y., Murayama, N., Shimada, M., Imaoka, S., Funae, Y., and Kato, R. Suppression of hepatic levels of an ethanol-inducible P-450DM/j by growth hormone: Relationship between the increased level of P-450DM/j and depletion of growth hormone in diabetes, 716
 Yang, S. K., *see* Lu, X.-L., 932
 Yasumoto, T., *see* Gusovsky, F., 44
 Yeh, G.-C., *see* Bonhaus, D. W., 273
 Yokota, T., Konno, K., Mori, S., Shigeta, S., Kumagai, M., Watanabe, Y., and Machida, H. Mechanism of selective inhibition of varicella zoster virus replication by 1- β -D-arabinofuranosyl-E-5-(2-bromovinyl)uracil, 312
 Yoshimura, A., *see* Akiyama, S.-I., 730

Z

- Zhou, Z., *see* Sommadossi, J.-P., 9
 Ziery, G. J., *see* Bijsterbosch, M. K., 484

A

Acetylcholine

- active transport inhibition, fractional vesamicol receptor occupancy, synaptic vesicles (*Torpedo*), 452
- inhibition of storage by acetylcholine analogs (*Torpedo*), 333
- parasympathectomy, guanine nucleotide binding proteins, cardiac ventricle (dog), 72

Acetylcholinesterase, irreversible inhibitor, onchidal, mechanism of action (fish), 349

Acetyl coenzyme A, bioactivation of cysteine-S-conjugate, tetrafluoroethylene, acylating reactive intermediates (rat), 654

Adenocarcinoma, mammary, 5-fluorouracil effect, thymidylate synthase-overproducing cells, 219

Adenosine, requirement, ethanol-induced heterologous desensitization, 744

Adenosine monophosphate, cyclic

- accumulation in PC12 and NCB-20 cells, phosphoinositide breakdown, maitotoxin, 44
- adenylate cyclase-coupled muscarinic receptors, agonist, 465
- agonist-stimulated accumulation, mutant β_2 -adrenergic receptors, no phosphorylation sites, 641
- coupling of GTP-binding protein G_s , synaptic membrane adenylate cyclase, chronic antidepressant treatment (rat), 803
- dependent protein kinase
 - cell line regulation, β_2 -adrenergic receptor, 248
 - heterologous desensitization, β -adrenergic receptor, 343
 - ethanol-induced heterologous desensitization, 744
 - prostaglandin-regulated metabolism, platelets, 866

Adenosine triphosphate

- dependent calcium ion uptake, taurine analogues, retina (rat), 256
- potassium channel opener RP 49356 and, competition on potassium channels, cardiac myocytes (guinea pig), 897
- sensitive binding of melittin, catalytic domain, protein kinase C (rat), 355

Adenovirus, gelonin conjugated to targeting molecules, cytotoxicity, 818

Adenylate cyclase

- activation, epinephrine binding frequency, 437
- adipocyte A_1 adenosine receptors, chronic exposure, A_1 adenosine receptor agonist (rat), 681
- coupled muscarinic receptors, agonist, selectivity, 465
- development of photoaffinity ligand, octopamine receptors (firefly), 34
- growth of S49 cell in low concentrations, β -adrenergic agonists, desensitization, 459
- prostaglandin-regulated cyclic AMP metabolism, platelets, 866
- synaptic membrane, coupling to GTP-binding protein, chronic antidepressant treatment (rat), 803

Adenylyl cyclase, dynorphin-selective inhibition, cerebellum membranes (guinea pig), 627

Adipocytes, adenosine A_1 receptor-adenylate cyclase system, chronic exposure, A_1 adenosine receptor agonist (rat), 681

Adrenoceptors

- α -1, activation, glycogen phosphorylase (rat), 166
- β
 - agonists, S49 cell growth and desensitization, 459
 - binding regulation, desipramine (rat), 211
 - epinephrine binding frequency, adenylate cyclase activation, 437
 - heterologous desensitization, cAMP-dependent protein kinase, 343
 - radioligands for labeling, dihydroalprenolol inadequacy (rat), 201
 - serotonin depletion, dihydroalprenolol binding in brain (rat), 903

 β -2

cAMP accumulation in cells, 641

regulation of cell line, cAMP-dependent protein kinase, 248

Agonists, nicotinic, nicotinic and muscarinic receptors (*Torpedo*), 177

Albumin, ceftriaxone binding, competition with bilirubin, 478

Alcohol, anesthetic effects on calcium stores, membrane order, brain microsomes (mouse), 471

Aldose reductase, -inhibitor reaction, involvement, sulfhydryl residues, 825

N-Alkylamide, neurotoxin, sodium channel activation, inhibition of batrachotoxin A-20- α -benzoate binding, 280

Alkylating agents, melphalan-resistant breast cancer cell line, resistance mechanism, DNA cross-link removal, 224

N-Alkylporphyrins, stereoselective inhibition, hepatic ferrochelatase (chick), 608Alprenolol, inadequacy of dihydroalprenolol, radioligands for labeling, β adrenoceptors (rat), 201

Ames test, mutagenicity, dimethyl heteroaromatic triazenes, 939

Amiloride analogues, inhibition of monoamine oxidase (rat), 296

3-Amino-1-hydroxy-2-pyrrolidone, 7-chlorokynurenic acid and, modes of action, NMDA-sensitive glutamate receptors (rat), 912

Amitriptyline, coupling of GTP-binding protein G_s , synaptic membrane adenylate cyclase (rat), 803

Amlodipine, positively charged, interactions with uncharged drugs, cardiac membranes, 634

Ammonium ions, temperature and, inhibition of peptide bond formation, chloramphenicol, 615

Amonafide, structural analogs and, topoisomerase II-mediated DNA cleavage, 371

Anesthetics, effect on calcium stores, membrane order, brain microsomes (mouse), 471

Antiarrhythmic drugs, class I, interaction, quinidine and lidocaine (rat), 150

Anticonvulsants, molecular determinants, benzodiazepine receptor affinities, 589

Antidepressants

coupling of stimulatory GTP-binding protein G_s , synaptic membrane adenylate cyclase (rat), 803

2-iodoimipramine, serotonin transporter (human), 620

regulation of β adrenoceptor binding, reevaluation, desipramine (rat), 211

tricyclic, dextromethorphan binding, phencyclidine receptor (rat), 160

Antineoplastic drugs, 1- β -D-arabinofuranosylcytosine enhancement, resistance, mammalian tissue culture cells, 360Antipsychotics, GTP-binding protein-modifying agents, multiple affinity binding states, σ receptors, 512

Antitumor drugs, topoisomerase II-mediated DNA cleavage, amonafide and its structural analogs, 371

Anti-vaccinia virus, potentiation by homocysteine, *S*-adenosylhomocysteine hydrolase inhibitor (mouse), 4901- β -D-Arabinofuranosylcytosine, enhancement of resistance to antineoplastic drugs, mammalian tissue culture cells, 3601- β -D-Arabinofuranosyl-*E*-5-(2-bromovinyl)uracil, inhibition of varicella zoster virus replication, 312

Arachidonic acid, role of protein kinase C in metabolism, Madin-Darby kidney cells (dog), 317

Aspartic acid, site-directed mutagenesis, m_1 muscarinic acetylcholine receptors, 840

Atropine, regulation of muscarinic receptor subtypes (rat), 749

3'-Azido-3'-deoxythymidine, cellular pharmacology, DNA incorporation, human bone marrow cells, 9

Azidopine, cyclosporine binding protein, multidrug resistance-related P-glycoprotein, 543

B

Batrachotoxin

quinidine and lidocaine, interaction, class I antiarrhythmic drug receptor (rat), 150

α -scorpion toxin and, stabilization, open state of single voltage-gated sodium channels, 789

Batrachotoxin A-20- α -benzoate, inhibition of binding, sodium channel activation, *N*-alkylamide neurotoxin, 280

3'-*O*-(4-Benzoyl)benzoyl adenosine 5'-triphosphate, irreversible action, phospholipase C-coupled P_{2U} -purinergic receptors, 831

Bilirubin, ceftriaxone binding, human serum albumin, 478

Bleomycin, acute pulmonary toxicity, DNA scission, matrix protein mRNA levels (mouse), 231

BM5, adenylate cyclase-coupled muscarinic receptors, selectivity, 465

Bone marrow, DNA incorporation, cellular pharmacology, 3'-azido-3'-deoxythymidine (human), 9

Bradykinin, -stimulated arachidonic acid metabolism, protein kinase C role, Madin-Darby kidney cells (dog), 317

Brain

dendrotoxin receptors, voltage-gated potassium channels (rat), 689

dihydroalprenolol binding, serotonin depletion (rat), 903

effects of polyamines, binding of MK-801, NMDA receptor, 575

high affinity binding sites, phencyclidine (guinea pig), 887

inositol-1,4,5-trisphosphate-induced calcium release, Ca^{2+} - or caffeine-induced Ca^{2+} calcium release, pharmacological differentiation, 673

kainate receptors, mercuric ions, noncompetitive antagonists (*Xenopus*), 582

microsomes

anesthetic effects, calcium stores (mouse), 471

inhibition of inositol 1,4,5-trisphosphate-induced calcium release, potassium channel blockers, 664

multiple opioid receptors, ligand selectivity profiles (guinea pig), 265

neuronal cultures, calcium-mediated neuronal death, veratridine (rat), 525

parathyroid gland and, glycoprotein nature, dopamine D1 receptors, 566

regulation of muscarinic receptor subtypes, atropine (rat), 749

type-A cholecystokinin binding sites (cow), 285

Breast neoplasms

μ class glutathione *S*-transferase activity, gene transfection (human), 22

methylphalan-resistant, resistance mechanism, DNA cross-link removal, 224

Bronchoconstriction, pulmonary B_2 bradykinin receptor (guinea pig), 1

tert-Butoxycarbonylcholecystokinin, sulfation, liver tyrosylprotein sulfotransferase (rat), 647

C

Cadmium, biochemical effects, NMR urinalysis studies (rat), 398

Caffeine, -induced Ca^{2+} release, inositol-1,4,5-trisphosphate-induced calcium release, pharmacological differentiation, 673

Calcium

delayed influx increase, glutamate, neuronal death (rat), 106

-dependent effects of maitotoxin, phosphoinositide breakdown, cyclic AMP accumulation, 44

glycogen phosphorylase activation, α_1 -adrenergic receptor subtypes (rat), 166

inositol-1,4,5-trisphosphate-induced release

Ca^{2+} - or caffeine-induced calcium release, pharmacological differentiation, 673

inhibition by potassium channel blockers, brain microsomes, 664

-mediated neuronal death, veratridine, brain neuronal cultures (rat), 525

mobilization

inositol tetrakisphosphate, cerebellum microsomes (rat), 391

phosphoinositide hydrolysis, thrombin and trypsin (chick), 142

stores, anesthetic effects, membrane order of brain microsomes (mouse), 471

uptake, taurine analogues, retina (rat), 256

Calcium channel, antagonist amlodipine, cardiac membrane interactions, 634

Cannabidiol, induction of liver cytochrome P-450, purification, characterization (mouse), 377

Capsid proteins, gelonin conjugated to targeting molecules, cytotoxicity, 818

2 β -Carbomethoxy-3 β -(4-fluorophenyl)tropane, labeling of cocaine receptors, 518

Carbonic anhydrase, NMR urinalysis studies, biochemical effects, cadmium (rat), 398

Carbovir, 2',3'-dideoxyinosine phosphorylation, cytosolic 5'-nucleotidase, lymphoid cells (human), 291

Cations, irradiation of dihydropyridine binding sites (mouse), 327

Caudate-putamen, labeling of cocaine receptors, 2 β -carbomethoxy-3 β -(4-fluorophenyl)tropane, 518

Ceftriaxone, binding to human serum albumin, competition with bilirubin, 478

Cerebellum

dynorphin-selective inhibition, adenylyl cyclase (guinea pig), 627

microsomes, calcium mobilization, inositol tetrakisphosphate (rat), 391

CGP12177

radioligands for labeling, *beta* adrenoceptors, dihydroalprenolol inadequacy (rat), 201

regulation of *beta* adrenoceptor binding, reevaluation, desipramine (rat), 211

Chloramphenicol, inhibition of peptide bond formation, temperature, concentration of ammonium ions, 615

Chlorethylclonidine, glycogen phosphorylase activation, α_1 -adrenergic receptor subtypes (rat), 166

Chloride, chronic clonazepam administration, GABA_A receptors, cortical neurons (chicken), 796

7-Chlorokynurenic acid, 3-amino-1-hydroxy-2-pyrrolidone and, modes of action, NMDA-sensitive glutamate receptors (rat), 912

3-(3-Cholamidopropyl)dimethylammonio-2-hydroxy-1-propanesulfonate, solubilization of muscarinic receptors (rat), 420

Cholecystokinin

CCK-A and CCK-B/gastrin receptors, requirements for activation, 881

sulfation of *tert*-butoxycarbonylcholecystokinin, liver tyrosylprotein sulfotransferase (rat), 647

type-A binding sites, brain (cow), 285

Cholesteryl hemisuccinate, muscarinic acetylcholine receptor binding, 601

Chromosome 7, *CYPOR* gene localization, NADPH-P450 oxidoreductase (human), 83

Cisplatin, μ class glutathione *S*-transferase activity, gene transfection, breast cancer cells (human), 22

Clonazepam, chronic administration, GABA_A receptor function, cortical neurons (chicken), 796

Colchicine

analogue, cytoplasmic microtubules, human neutrophil degranulation, 547

cyclosporine binding protein, multidrug resistance-related P-glycoprotein, 543

Computer models, three-dimensional steric molecular modeling, 5-hydroxytryptamine₂ receptor pharmacophore, 505

Creatinuria, NMR urinalysis studies, biochemical effects, cadmium (rat), 398

Cyclic AMP, *see* Adenosine monophosphate, cyclic

Cyclosporine, binding protein, multidrug resistance-related P-glycoprotein, 543
 Cysteine-S-conjugate, bioactivation, tetrafluoroethylene, acylating reactive intermediates (rat), 654
 Cytochrome Cyp1A2, regulatory elements, response to 3-methylcholanthrene (human), 66
 Cytochrome P-450
 flavin-containing monooxygenase, enantioselective *N*-oxygenation, verapamil (hog, rat), 497
 mutagenicity of dimethyl heteroaromatic triazenes, mutagenicity, Ames test, 939
 purification and characterization, induction by cannabidiol, liver (mouse), 377
 stereoselective inhibition of hepatic ferrochelatase, *N*-alkylated porphyrins (chick), 608
 suppression of constitutive gene expression, endotoxin response, liver (rat), 699
 Cytochrome P-450DM/j, ethanol-inducible, suppression of hepatic levels, growth hormone (rat), 716
 Cytochrome P450IA1
 induction and localization, endothelium of vertebrate heart (teleost), 723
 2-iodo-3,7,8-trichlorodibenzo-*p*-dioxin binding species, Ah receptor agonists, liver (mouse), 113, 121
 Cytochrome P450IIE1, IIE2 gene and, tissue-specific expression, induction (rabbit), 61
 Cytochrome P450III, identification, polymorphically expressed member (human), 97
 Cytochrome P450IIIA4, oxidation, midazolam and triazolam (human), 89
 Cytoplasm, microtubules, colchicine analogue, human neutrophil degranulation, 547

D

Degranulation, human neutrophil, cytoplasmic microtubules, colchicine analogue, 547
 Dendrotoxin, binding and receptor solubilization (rat), 689
 Desipramine
 coupling of GTP-binding protein G_{α} , synaptic membrane adenylate cyclase (rat), 803
 regulation of β adrenoceptor binding, reevaluation (rat), 211
 Detergent, 3-(3-cholamidopropyl)dimethylammonio-2-hydroxy-1-propanesulfonate, solubilization, muscarinic receptors (rat), 420
 Dexamethasone, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-mediated binding decrease, hepatic cytosolic glucocorticoid receptor (rat), 239
 Dextromethorphan, tricyclic antidepressants and, higher affinity binding, phencyclidine receptor (rat), 160
 Diabetes, ethanol-inducible P-450DM/j, suppression of hepatic levels, growth hormone (rat), 716
 Dideoxyadenosine, permeation and salvage, mammalian cells (mouse), 185
 2',3'-Dideoxyinosine, phosphorylation by cytosolic 5'-nucleotidase, lymphoid cells (human), 291
 Dihydroalprenolol
 binding in brain, serotonin depletion (rat), 903
 regulation of β adrenoceptor binding, reevaluation, desipramine (rat), 211
 Dihydropyridine, modulation of binding sites, radiation, discrete cation binding site (mouse), 327
 1,4-Dihydropyridine, calcium channel antagonist amlodipine, membrane interactions, heart, 634
 9-(*trans*-2',*trans*-3'-Dihydroxycyclopent-4'-enyl)-adenine, antiviral effects of homocysteine (mouse), 490
 Dilazep, interaction, nucleoside transporter binding sites, S49 cells (mouse), 134
 Diltiazem
 cyclosporine binding protein, multidrug resistance-related P-glycoprotein, 543

 delayed increase of calcium influx, glutamate, neuronal death (rat), 106
 7,12-Dimethylbenz[*a*]anthracene, -induced immunosuppression, molecular mechanism (mouse), 128
 Dimethyl heteroaromatic triazenes, mutagenicity in Ames test, 939
 2,2-Diphenylpropionate, α -substituted antimuscarinics, distance geometry, 766
 Dipyrindamole, M&B 22,948 and, inhibition and stimulation, photoreceptor phosphodiesterases, 773
 DNA
 cleavage, topoisomerase II mediation, amonafide and analogs, 371
 cross-link removal, resistance, breast cancer cell line, 224
 incorporation of human bone marrow cells, cellular pharmacology, 3'-azido-3'-deoxythymidine, 9
 scission, acute pulmonary toxicity, bleomycin (mouse), 231
 single-strand breaks, oxidative stress, hepatocyte killing (rat), 193
 topoisomerase II effects, podophyllotoxin analogs, tubulin polymerization (human), 78
 DNA, complementary, dopamine D2 receptor, functional characterization (rat), 446
 DNA polymerase, inhibition of varicella zoster virus replication, 1 β -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil, 312
 Dopamine
 high affinity binding sites, phencyclidine, brain (guinea pig), 887
 labeling of cocaine receptors, 2 β -carbomethoxy-3 β -(4-fluorophenyl)tropane, 518
 Drug delivery, site-specific, lactosylated low density lipoprotein, Kupfer cells, 484
 Drug resistance, *see also* Multidrug resistance
 1- β -D-arabinofuranosylcytosine enhancement, antineoplastic drugs, mammalian tissue culture cells, 360
 Dynorphin, -selective inhibition of adenylyl cyclase, cerebellum membranes (guinea pig), 627

E

Encephalopathy, ceftriaxone binding, human serum albumin, 478
 Endothelium, vertebrate heart, cytochrome P450IA1 induction, localization (teleost), 723
 Endotoxin, acute phase response in liver, suppression, constitutive cytochrome P-450 gene expression (rat), 699
 Epidermal cells, phorbol ester-caused ornithine decarboxylase induction, inhibition by H-7 (mouse), 917
 Epidermal growth factor
 phorbol ester-caused suppression of binding, failure to inhibit, H-7 (mouse), 917
 tyrosine kinase activity, inhibition in epidermoid cells, psoralen/ultraviolet light treatment, 848
 Epidermoid cells, psoralen/ultraviolet light treatment, inhibition, EGF receptor tyrosine kinase activity, 848
 Epilepsy, quinoxalines and kynurenines, glycine site antagonists, NMDA receptors (rat), 430
 Epinephrine
 binding frequency, activation, adenylate cyclase, 437
 growth of S49 cells in low concentrations, β -adrenergic agonists, desensitization, 459
 -stimulated arachidonic acid metabolism, protein kinase C role, Madin-Darby kidney cells (dog), 317
 Ethanol
 -induced heterologous desensitization, adenosine, 744
 -inducible P-450DM/j, suppression of hepatic levels, growth hormone (rat), 716
 Eugenol, inhibition of prostaglandin H synthase, 809
 Extracellular matrix, protein mRNA levels, acute pulmonary toxicity, bleomycin (mouse), 231

F

Ferrochelatase, hepatic, stereoselective inhibition, *N*-alkylated porphyrins (chick), 608

Flavin, -containing monooxygenase, enantioselective *N*-oxygenation, verapamil (hog, rat), 497
 Flunarizine, calcium-mediated neuronal death, veratridine, brain neuronal cultures (rat), 525
 5-Fluoro-2'-deoxyuridine, 1- β -D-arabinofuranosylcytosine enhancement, resistance, mammalian tissue culture cells, 360
 5-Fluorouracil, inhibition of thymidylate synthetase, enzyme-overproducing cells, resistance to 10-propargyl-5,8-dideazafolate, 219
 FMLP, desensitization of receptors, HL-60 cells, 384
 Folypolyglutamate synthetase, liver, relative substrate activities, pteridine/quinazoline/pyrimidine analogs (mouse), 736

G

Gangliosides, delayed increase of calcium influx, glutamate, neuronal death (rat), 106
 Gelonin, conjugated to targeting molecules, cytotoxicity, 818
 Gene, *CYPOR*, chromosome 7, localization and NADPH-P450 oxidoreductase (human), 83
 Glucose oxidase, hepatocyte killing and oxidative stress, single-strand DNA breaks (rat), 193
 Glutamate
 binding of MK-801 to NMDA receptor, effects of polyamines, 575
 delayed increase of calcium influx, neuronal death (rat), 106
 mercuric ions as noncompetitive antagonists, kainate receptors (*Xenopus*), 582
 L-Glutamate, tricyclic antidepressants and dextromethorphan, higher affinity binding, phencyclidine receptor (rat), 160
 Glutathione *S*-transferase, μ class activity, breast cancer cells, gene transfection (human), 22
 Glycine
 coagonist site, activation, NMDA receptors (*Xenopus*), 556
 regulation of *N*-methyl-D-aspartate receptor, ion channel, hippocampal membranes (rat), 273
 site antagonists, quinoxalines and kynurenines, NMDA receptors (rat), 430
 spermine-enhanced binding, NMDA receptor complex, 836
 Glycogen phosphorylase, activation, α_1 -adrenergic receptor subtypes (rat), 166
 Glycoproteins, nature of dopamine D1 receptors, brain and parathyroid gland, 566
 Golgi apparatus, sulfation of *tert*-butoxycarbonylcholecystokinin, liver tyrosylprotein sulfotransferase (rat), 647
 G-proteins
 adipocyte A₁ adenosine receptors, adenylate cyclase system (rat), 681
 density gradient profiles, adenosine A₁ receptors (calf), 412
 desensitization of FMLP receptors, HL-60 cells, 384
 solubilization of muscarinic receptors, 3-(3-cholamidopropyl)dimethylammonio-2-hydroxy-1-propanesulfonate (rat), 420
 Growth hormones, suppression of hepatic levels, ethanol-inducible P-450DM/j, diabetes (rat), 716
 GTP-binding protein
 coupling to synaptic membrane adenylate cyclase, chronic antidepressant treatment (rat), 803
 -modifying agents, multiple affinity binding states, σ receptors, 512

H

H-7, inhibition of phorbol ester-caused ornithine decarboxylase induction, failure to inhibit suppression of EGF binding, epidermal cells (mouse), 917
 HA-966, *see* 3-Amino-1-hydroxy-2-pyrrolidone
 Haloperidol, GTP-binding protein-modifying agents, multiple affinity binding states, σ receptors, 512
 Heart
 cardiac myocytes, ATP and RP 49356, competition on potassium channels, 897
 membrane, calcium channel antagonist interactions, 634

 ventricle, guanine nucleotide binding proteins, parasympathectomy (dogs), 72
 vertebrate, cytochrome P450IA1 induction, endothelium (teleost), 723
 Heparin, calcium mobilization, inositol tetrakisphosphate, cerebellum microsomes (rat), 391
 Hepatocytes
 killing, oxidative stress, DNA single-strand breaks (rat), 193
 vesicular uptake system, cation lucigenin (rat), 537
 Hippocampus
 N-methyl-D-aspartate receptor-gated ion channel, glycine regulation (rat), 273
 quinoxalines and kynurenines, glycine site antagonists, NMDA receptors (rat), 430
 HL-60 cells, desensitization, FMLP receptors, 384
 Homocysteine, potentiation of anti-vaccinia virus, *S*-adenosylhomocysteine hydrolase inhibitor (mouse), 490
 Human immunodeficiency virus, 2',3'-dideoxyinosine phosphorylation, cytosolic 5'-nucleotidase, lymphoid cells (human), 291
 3-Hydroxyprazepam, stereoselective formation, *N*-dealkylation, liver microsomes (rat), 932
 5-Hydroxytryptamine₃, receptor pharmacophore, three-dimensional steric molecular modeling, 505

I

Ifenprodil, novel NMDA receptor antagonist, interaction with polyamines (rat), 758
 Immunosuppression, 7,12-dimethylbenz[*a*]anthracene-induced, molecular mechanism (mouse), 128
 Immunotoxins, gelonin conjugated to targeting molecules, cytotoxicity, 818
 Inositol-1,4,5-trisphosphate
 -induced calcium release
 Ca²⁺- or caffeine-induced calcium release, pharmacological differentiation, 673
 inhibition by potassium channel blockers, brain microsomes, 664
 Inositol tetrakisphosphate, calcium mobilization, cerebellum microsomes (rat), 391
 Insecticides
 irreversible inhibitor of acetylcholinesterase, onchidal, mechanism of action (fish), 349
 sodium channel activation, inhibition of batrachotoxin A-20 α -benzoate binding, 280
 Interleukin 2, 7,12-dimethylbenz[*a*]anthracene-induced immunosuppression, molecular mechanism (mouse), 128
 2-Iodo-3,7,8-trichlorodibenzo-*p*-dioxin, binding species in liver, Ah receptor agonists (mouse), 113, 121
 2-Iodo-4-azidophenol, photoaffinity labeling, liver thermostable phenol sulfotransferase (human), 856
 2-Iodoimipramine, ligand for serotonin transporter (human), 620
 Iprindole, coupling of GTP-binding protein G_s, synaptic membrane adenylate cyclase (rat), 803
 Isoprenoid, synthetic photoaffinity labeling, P-glycoprotein, multidrug-resistant cells, 730

K

KB cells, podophyllotoxin analogs, tubulin polymerization, DNA topoisomerase II (human), 78
 Kidney
 microtubule assembly, phenytoin teratogenic action, embryo (sea urchin), 708
 Madin-Darby cells, role of protein kinase C, arachidonic acid metabolism (dog), 317
 NMR urinalysis studies, biochemical effects, cadmium (rat), 398
 Kupffer cells, site-specific drug delivery, lactosylated low density lipoprotein, 484

Kynurenines, quinoxalines and, glycine site antagonists, NMDA receptors (rat), 430

L

Lidocaine, quinidine and, interaction, class I antiarrhythmic drug receptor (rat), 150

Ligands

- binding subunit identification, 5-HT_{1A} receptor, radioiodinated photoaffinity probe (human), 15
- molecular determinants, benzodiazepine receptor affinities, 589
- photoaffinity, development, octopamine receptors (firefly), 34
- selectivity profiles, multiple opioid receptors (guinea pig), 265
- serotonin transporter, 2-iodoimipramine (human), 620

Lipid, environment and differential affinity, cerebral and atrial muscarinic acetylcholine receptors, pirenzepine, 601

Lipoprotein, lactosylated low density, potential carrier, site-specific drug delivery to Kupffer cells, 484

Liver

- acute phase response to endotoxin, suppression, constitutive cytochrome P-450 gene expression (rat), 699
- CYPOR gene localization, NADPH-P450 oxidoreductase (human), 83
- cytochrome P450III family, identification, polymorphically expressed member (human), 97
- cytochrome P450III_{A4}, oxidation, midazolam and triazolam (human), 89
- cytosolic glucocorticoid receptor, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, dexamethasone binding (rat), 239
- folylpolyglutamate synthetase, relative substrate activities, pteridine/quinazoline/pyrimidine analogs (mouse), 736
- 2-iodo-3,7,8-trichlorodibenzo-*p*-dioxin binding species, Ah receptor agonists (mouse), 113, 121
- microsomes, *see* Microsomes
- stereoselective inhibition of hepatic ferrochelatase, *N*-alkylate porphyrins (chick), 608
- suppression of levels, ethanol-inducible P-450DM/j, growth hormone (rat), 716
- thermostable phenol sulfotransferase, photoaffinity labeling, 2-iodo-4-azidophenol (human), 856
- tyrosylprotein sulfotransferase, sulfation, *tert*-butoxycarbonylchole-cystokinin (rat), 647
- zonal distribution of lucigenin, taurocholate influence (rat), 532

Lucigenin

- vesicular uptake, hepatocytes (rat), 537
- zonal distribution in liver, taurocholate influence (rat), 532

Lung, acute pulmonary toxicity of bleomycin, DNA scission, matrix protein mRNA levels (mouse), 231

LY186126, analysis of binding sites, ventricular myocardium (sheep, rabbit), 302

Lymphoid cells, 2',3'-dideoxyinosine phosphorylation, cytosolic 5'-nucleotidase (human), 291

Lymphoma

- epinephrine binding frequency, adenylate cyclase activation, 437
- growth of S49 cells in low concentrations, β -adrenergic agonists, desensitization, 459
- nucleoside transporter-associated binding sites, dilazep interaction, S49 cells (mouse), 134

M

Magnesium

- desensitization of FMLP receptors, HL-60 cells, 384
- tricyclic antidepressants and dextromethorphan, higher affinity binding, phencyclidine receptor (rat), 160

Maitotoxin, calcium-dependent effects, phosphoinositide breakdown, cyclic AMP accumulation, 44

Mammalian cells, permeation and salvage, dideoxyadenosine (mouse), 185

Manolide, structure-activity studies, pharmacore, phospholipase A₂ inactivation, 782

M&B 22,948, dipyrindamole and, inhibition and stimulation, photoreceptor phosphodiesterases, 773

MDCK cells, role of protein kinase C, arachidonic acid metabolism (dog), 317

Melittin, ATP-sensitive binding, catalytic domain, protein kinase C (rat), 355

Melphalan

- μ class glutathione *S*-transferase activity, gene transfection, breast cancer cells (human), 22

- resistant breast cancer cell line, resistance mechanism, DNA cross-link removal, 224

Menadione, hepatocyte killing and oxidative stress, single-strand DNA breaks (rat), 193

β -Mercaptoethanol, involvement of sulfhydryl residues, aldose reductase-inhibitor interaction, 825

Mercapturic acid, bioactivation of cysteine-*S*-conjugate, tetrafluoroethylene, acylating reactive intermediates (rat), 654

Mercuric ions, noncompetitive antagonists, kainate receptors, human brain (*Xenopus*), 582

Methotrexate, 1- β -D-arabinofuranosylcytosine enhancement, resistance, mammalian tissue culture cells, 360

Methoxamine, glycogen phosphorylase activation, α_1 -adrenergic receptor subtypes (rat), 166

2-Methoxy-5-(2',3',4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one, cytoplasmic microtubules, human neutrophil degranulation, 547

N-Methyl-D-aspartate

- high affinity binding sites, phencyclidine, brain (guinea pig), 887
- sensitive glutamate receptors, modes of action, HA-966 and 7-chlorokynurenic acid (rat), 912

3-Methylcholanthrene, regulatory elements, cytochrome Cyp1A2 gene (human), 66

Microsomes

brain

- anesthetic effects, calcium stores (mouse), 471
- inhibition of inositol 1,4,5-trisphosphate-induced calcium release, potassium channel blockers, 664

- cerebellum, calcium mobilization, inositol tetrakisphosphate (rat), 391

- induction of liver cytochrome P-450, cannabidiol, characterization (mouse), 377

- liver, metabolism of prazepam (rat), 932

Microtubules

- assembly, phenytoin teratogenic action, embryo (sea urchin), 708
- cytoplasmic, human neutrophil degranulation, colchicine analogue, 547

- stabilized, vinblastine binding, 366

Midazolam, triazolam and, oxidation, liver cytochrome P450III_{A4} (human), 89

Mitochondria, quantitation of monoamine oxidases A and B, human placenta, 54

MK-801

- binding to NMDA receptor, effects of polyamines, 575
- delayed increase of calcium influx, glutamate, neuronal death (rat), 106

- ifenprodil, interaction with polyamines (rat), 758

Monensin, gelonin conjugated to targeting molecules, cytotoxicity, 818

Monoamine oxidase

- A and B, quantitation, mitochondria from placenta (human), 54
- inhibition by amiloride analogues (rat), 296

Monoclonal antibodies, quantitation of monoamine oxidases A and B, mitochondria, human placenta, 54

Monoxygenase, flavin-containing, enantioselective *N*-oxygenation, verapamil (hog, rat), 497

Multidrug resistance, *see also* Drug resistance

- μ class glutathione *S*-transferase activity, gene transfection, breast cancer cells (human), 22

Multidrug resistance—*continued*

- related P-glycoprotein, cyclosporine binding protein, 543
- synthetic isoprenoid photoaffinity labeling, P-glycoprotein, 730
- Muscarinic antagonists, rank order of potency, variation with time, pancreas (rat), 405
- Muscle, inositol-1,4,5-trisphosphate-induced calcium release, Ca^{2+} - or caffeine-induced Ca^{2+} release, pharmacological differentiation, 673
- Mutagenesis
 - heterologous desensitization, β -adrenergic receptor, cAMP-dependent protein kinase, 343
 - site-directed, m_1 muscarinic acetylcholine receptors, 840
- Myocardium, ventricular, analysis of binding sites, LY186126 (sheep, rabbit), 302
- Myocytes, cardiac, ATP and RP 49356, competition on potassium channels, 897

N

- NADPH-P450 oxidoreductase, localization, *CYPOR* gene to chromosome 7 (human), 83
- Naloxone, dynorphin-selective inhibition, adenylyl cyclase, cerebellum membranes (guinea pig), 627
- NCB-20 cells, cyclic AMP accumulation, phosphoinositide breakdown, maitotoxin, 44
- Neuronal death, delayed increase of calcium influx, glutamate (rat), 106
- Neurons, cortical, chronic clonazepam administration, GABA_A receptors (chicken), 796
- Neuropeptides, secretin family, tyrosine hydroxylase activity, PC12 cells (rat), 925
- Neurotoxins, batrachotoxin and α -scorpion toxin, stabilization, voltage-gated sodium channels, 789
- Neutrophils, degranulation, cytoplasmic microtubules, colchicine analogue, 547
- Nitrendipine, delayed increase of calcium influx, glutamate, neuronal death (rat), 106
- Nor-binaltorphimine, dynorphin-selective inhibition, adenylyl cyclase, cerebellum membranes (guinea pig), 627
- Nuclear magnetic resonance, urinalysis studies, biochemical effects, cadmium (rat), 398
- Nucleosides
 - permeation and salvage, dideoxyadenosine, mammalian cells (mouse), 185
 - transporter-associated binding sites, dilazep interaction, S49 cells (mouse), 134
- 5'-Nucleotidase, cytosolic, 2',3'-dideoxyinosine phosphorylation, lymphoid cells (human), 291

O

- Octopamine, receptors, development, photoaffinity ligand (firefly), 34
- Onchidal, novel mechanism of action (fish), 349
- Oocytes
 - activation of glycine coagonist site, NMDA receptors (*Xenopus*), 556
 - mercuric ions, noncompetitive antagonists, human brain (*Xenopus*), 582
- Ornithine decarboxylase, phorbol ester-caused suppression of binding, inhibition of induction, H-7 (mouse), 917

P

- Pancreas, muscarinic antagonists, rank order of potency, variation with time (rat), 405
- Parasympathectomy, quantity of guanine nucleotide binding proteins, cardiac ventricle (dogs), 72
- Parathyroid gland, brain and, glycoprotein nature, dopamine D1 receptors, 566
- Patch clamp, batrachotoxin and α -scorpion toxin, stabilization, voltage-gated sodium channels, 789

- PC12 cells
 - cyclic AMP accumulation, phosphoinositide breakdown, maitotoxin, 44
 - regulation of tyrosine hydroxylase activity, neuropeptides, secretin family (rat), 925
- Pentobarbital, enantiomers, actions, nicotinic cholinergic receptors, 874
- Peptidyltransferase, inhibition of peptide bond formation, temperature and ammonium ions, chloramphenicol, 615
- Pertussis toxin
 - dopamine D2 receptor cDNA, functional characterization (rat), 446
 - GTP-binding protein-modifying agents, multiple affinity binding states, σ receptors, 512
- P-glycoprotein
 - multidrug-resistant cells
 - cyclosporine binding protein, 543
 - synthetic isoprenoid photoaffinity labeling, 730
- Phencyclidine
 - delayed increase of calcium influx, glutamate, neuronal death (rat), 106
 - high affinity binding sites in brain (guinea pig), 887
- Phenobarbital, induction of liver cytochrome P-450, cannabidiol, characterization (mouse), 377
- Phenolic peroxidase, substrates, inhibition of prostaglandin H synthase, eugenol, 809
- Phenol sulfotransferase
 - immunological characterization (human, monkey, rat, mouse, guinea pig, frog), 29
 - thermostable, photoaffinity labeling, liver (human), 856
- Phenytol, teratogenic action, microtubule assembly, embryo (sea urchin), 708
- Phorbol ester
 - caused ornithine decarboxylase induction, inhibition of induction, H-7 (mouse), 917
 - delayed increase of calcium influx, glutamate, neuronal death (rat), 106
- Phosphatidylcholine, muscarinic acetylcholine receptor binding, 601
- Phosphatidylinositol hydrolysis, glycogen phosphorylase activation, α_1 -adrenergic receptor subtypes (rat), 166
- Phosphodiesterase
 - inhibitor LY186126, binding site analysis, ventricular myocardium (sheep, rabbit), 302
 - photoreceptor, inhibition and stimulation, dipyrindamole and M&B 22,948, 773
 - prostaglandin-regulated cyclic AMP metabolism, platelets, 866
- Phosphoinositide
 - adenylate cyclase-coupled muscarinic receptors, agonist, selectivity, 465
 - breakdown, calcium-dependent effects, maitotoxin, 44
 - hydrolysis, calcium mobilization, thrombin and trypsin (chick), 142
- Phospholipase A₂, inactivation, structure-activity studies, manolide, 782
- Phospholipase C, -coupled P_{2Y}-purinergic receptors, irreversible action, 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate, 831
- N-(Phosphonoacetyl)-L-aspartate, 1- β -D-arabinofuranosylcytosine enhancement, resistance, mammalian tissue culture cells, 360
- Phosphorylation, lack of sites on mutant β_2 -adrenergic receptors, altered patterns, cAMP accumulation, 641
- Photoaffinity labeling
 - 2-iodo-4-azidophenol, liver thermostable phenol sulfotransferase (human), 856
 - ligand-binding subunit identification, 5-hydroxytryptamine_{1A} receptor (human), 15
 - ligand development, octopamine receptors (firefly), 34
- Photoreceptors, phosphodiesterases, inhibition and stimulation, dipyrindamole and M&B 22,948, 773
- Physostigmine, nucleoside transporter-associated binding sites, dilazep interaction, S49 cells (mouse), 134

- Pirenzepine, muscarinic acetylcholine receptor binding, lipid environment, 601
- Placenta, quantitation of monoamine oxidases A and B, mitochondria (human), 54
- Platelets
ligand for serotonin transporter, 2-iodoimipramine (human), 620
prostaglandin-regulated cyclic AMP metabolism, 866
- Podophyllotoxin, analogs, DNA topoisomerase II effects, tubulin polymerization (human), 78
- Polyamines
binding of MK-801 to NMDA receptor, 575
interaction with ifenprodil (rat), 758
- Porphyrins, *N*-alkylated, stereoselective inhibition, hepatic ferrochelatase (chick), 608
- Potassium channel
competition between ATP and RP 49356, cardiac myocytes (guinea pig), 897
voltage-gated, brain dendrotoxin receptors (rat), 689
- Potassium channel blockers, inhibition of inositol 1,4,5-trisphosphate-induced calcium release, brain microsomes, 664
- Przepam, metabolism by liver microsomes (rat), 932
- 10-Propargyl-5,8-dideazafolate, resistance in enzyme-overproducing cells, thymidylate synthetase, inhibition by 5-fluorouracil, 219
- Prostaglandin, -regulated cyclic AMP metabolism, platelets, 866
- Prostaglandin H synthase, mechanism of inhibition by eugenol, phenolic peroxidase substrates, 809
- Protein kinase
cAMP-dependent
cell line regulation, β_2 -adrenergic receptor, 248
heterologous desensitization, β -adrenergic receptor, 343
- Protein kinase C
catalytic domain, ATP-sensitive binding, melittin (rat), 355
delayed increase of calcium influx, glutamate, neuronal death (rat), 106
role in epinephrine- and bradykinin-stimulated arachidonic acid metabolism, Madin-Darby kidney cells (dog), 317
- Psoralen, -ultraviolet treatment, inhibition of EGF receptor tyrosine kinase, epidermoid cells, 848
- Pteridine, pyrimidine analogs and quinazoline, relative substrate activities, liver folylpolyglutamate synthetase (mouse), 736
- ### Q
- Quinidine, lidocaine and, interaction, class I antiarrhythmic drug receptor (rat), 150
- Quinoxalines, kynurenines and, glycine site antagonists, NMDA receptors (rat), 430
- Quinuclidinylbenzylate, muscarinic acetylcholine receptor binding, lipid environment, 601
- ### R
- Radiation, inactivation, cation binding sites, dihydropyridine binding (mouse), 327
- Radioligands, labeling of CNS β -adrenergic receptors, inadequacy, dihydroalprenolol (rat), 201
- Receptors
 σ , multiple affinity binding states, 512
adenosine A_1
adipocytes, adenylate cyclase system (rat), 681
density gradient profiles (calf), 412
adrenergic, *see* Adrenoceptors
Ah, 2-iodo-3,7,8-trichlorodibenzo-*p*-dioxin binding species, liver (mouse), 113, 121
antiarrhythmic drug class I, interaction, quinidine and lidocaine (rat), 150
benzodiazepine, molecular determinants, anticonvulsant activities, 589
bradykinin B_2 , pulmonary evidence (guinea pig), 1
cocaine, labeling, 2 β -carbomethoxy-3 β -(4-fluorophenyl)tropane, 518
dendrotoxin, voltage-gated potassium channels, brain (rat), 689
desensitization, ethanol-induced, adenosine, 744
dopamine D1, glycoprotein nature, brain and parathyroid gland, 566
dopamine D2, cDNA, mammalian cell line (rat), 446
formyl peptide, desensitization, HL-60 cells, 384
GABA $_A$, chronic clonazepam administration, cortical neurons (chicken), 796
gastrin, activation, CCK-A and CCK-B, 881
glucocorticoid, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, dexamethasone binding (rat), 239
glutamate, modes of action, HA-966 and 7-chlorokynurenine acid (rat), 912
5-hydroxytryptamine, pharmacophore, three-dimensional steric molecular modeling, 505
5-hydroxytryptamine $_{1A}$, ligand-binding subunit identification (human), 15
kainate, mercuric ions, noncompetitive antagonists (*Xenopus*), 582
N-methyl-D-aspartate
activation, glycine coagonist site (*Xenopus*), 556
binding of MK-801, effects of polyamines, 575
glycine regulation of ion channel, hippocampal membranes (rat), 273
quinoxalines and kynurenines, glycine site antagonists (rat), 430
spermine, binding to glycine site, 836
muscarinic
adenylate cyclase-coupled, selectivity, 465
potency of antagonists, pancreas (rat), 405
regulation of subtypes, atropine (rat), 749
solubilization, 3-(3-cholamidopropyl)dimethylammonio-2-hydroxyl-1-propanesulfonate (rat), 420
 α -substituted 2,2-diphenylpropionate antimuscarinics, distance geometry, 766
muscarinic acetylcholine
cerebral and atrial, lipid environment, 601
 m_1 , site-directed mutagenesis, 840
nicotinic and muscarinic, semigrad nicotinic agonists, binding (*Torpedo*), 177
nicotinic cholinergic, actions, pentobarbital enantiomers, 874
NMDA
ifenprodil, interaction with polyamines (rat), 758
tricyclic antidepressants, dextromethorphan (rat), 160
octopamine, development, photoaffinity ligand (firefly), 34
opioid
dynorphin-selective inhibition, adenylyl cyclase (guinea pig), 627
multiple, ligand selectivity profiles (guinea pig), 265
phencyclidine, tricyclic antidepressants and dextromethorphan binding (rat), 160
P $_{2U}$ -purinergic, irreversible activation, 831
vesamicol, acetylcholine active transport inhibition, synaptic vesicles (*Torpedo*), 452
Retina, effects of taurine analogues on calcium uptake (rat), 256
Ricin B-chain, gelonin conjugated to targeting molecules, cytotoxicity, 818
RNA, messenger
adipocyte A_1 adenosine receptors, adenylate cyclase system (rat), 681
matrix protein levels, acute pulmonary toxicity, bleomycin (mouse), 231
mercuric ions as noncompetitive antagonists, kainate receptors (*Xenopus*), 582
tissue-specific expression, cytochrome P450IIE1 and IIE2 genes (rabbit), 61
RP 49356, adenosine triphosphate and, competition on potassium channels, cardiac myocytes (guinea pig), 897
- ### S
- Sarcoplasmic reticulum, inositol-1,4,5-trisphosphate-induced calcium release, Ca $^{2+}$ - or caffeine-induced Ca $^{2+}$ calcium release, pharmacological differentiation, 673

- S49 cells
 dilazep binding, nucleoside transporter-associated sites (mouse), 134
 growth in low concentrations, β -adrenergic agonists, desensitization, 459
 α -Scorpion toxin, batrachotoxin and, stabilization, open state of single voltage-gated sodium channels, 789
 Secretin, neuropeptides, tyrosine hydroxylase activity, PC12 cells (rat), 925
 Serotonin
 depletion, component of dihydroalprenolol binding, brain (rat), 903
 5-hydroxytryptamine₂ receptor pharmacophore, three-dimensional steric molecular modeling, 505
 transporter, 2-iodoimipramine (human), 620
 Sodium, ligand for serotonin transporter, 2-iodoimipramine (human), 620
 Sodium channel
 inhibition of batrachotoxin A-20- α -benzoate binding, *N*-alkylamide neurotoxin, 280
 voltage-gated, stabilization, batrachotoxin and α -scorpion toxin, 789
 Spermine
 binding at glycine site, NMDA receptor complex, 836
 binding of MK-801 to NMDA receptor, effects of polyamines, 575
 Sucrose, density gradient profiles, adenosine A₁ receptors (calf), 412
 Sulfhydryl residues, involvement, aldose reductase-inhibitor reaction, 825
 Synaptic vesicles
 acetylcholine active transport inhibition, fractional vesamicol receptor occupancy (*Torpedo*), 452
 inhibition of acetylcholine storage, acetylcholine analogs (*Torpedo*), 333
- T**
- Taurine, analogues, calcium uptake, retina (rat), 256
 Taurocholate, zonal distribution of lucigenin, liver (rat), 532
 Taxol, vinblastine binding, stabilized microtubules, 366
 Temperature, ammonium ion concentration and, inhibition of peptide bond formation, chloramphenicol, 615
 Testis, NMR urinalysis studies, biochemical effects, cadmium (rat), 398
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, -mediated decreases in dexamethasone binding, hepatic cytosolic glucocorticoid receptor (rat), 239
 Tetrafluoroethylene, bioactivation of cysteine-*S*-conjugate, mercapturic acid, acylating reactive intermediates (rat), 654
 Thrombin, trypsin and, phosphoinositide hydrolysis, calcium mobilization (chick), 142
 Thymidine kinase, inhibition of varicella zoster virus replication, 1- β -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil, 312
 Thymidylate synthetase, inhibition by 5-fluorouracil, enzyme-over-producing cells, resistance to 10-propargyl-5,8-dideazafolate, 219
 Topoisomerase II
 -mediated DNA cleavage, amonafide and its structural analogs, 371
 podophyllotoxin analogs, tubulin polymerization (human), 78
 Toxins, μ class glutathione *S*-transferase activity, gene transfection, breast cancer cells (human), 22
 Triazolam, midazolam and, oxidation, liver cytochrome P450III_{A4} (human), 89
 Trypsin, thrombin and, phosphoinositide hydrolysis, calcium mobilization (chick), 142
 Tubulin, vinblastine binding, stabilized microtubules, 366
 Tyrosine hydroxylase, regulation of activity in PC12 cells, neuropeptides, secretin family (rat), 925
 Tyrosine kinase, inhibition in A431 human epidermoid cells, psoralen/ultraviolet treatment, 848
 Tyrosylprotein sulfotransferase, liver, sulfation, *tert*-butoxycarbonyl-cholecystokinin (rat), 647
- U**
- Ultraviolet light, psoralen treatment, inhibition of EGF receptor tyrosine kinase, epidermoid cells, 848
- V**
- Vaccinia virus
 antiviral effects of homocysteine, *S*-adenosylhomocysteine hydrolase inhibitor (mouse), 490
 CYPOR gene localization, NADPH-P450 oxidoreductase (human), 83
 Vagotomy, parasympathectomy, guanine nucleotide binding proteins, cardiac ventricle (dogs), 72
 Varicella zoster virus, inhibition of replication, 1- β -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil, 312
 Ventricle, cardiac, guanine nucleotide binding proteins, parasympathectomy (dog), 72
 Verapamil
 cyclosporine binding protein, multidrug resistance-related P-glycoprotein, 543
 delayed increase of calcium influx, glutamate, neuronal death (rat), 106
 enantioselective *N*-oxygenation, hepatic flavin-containing monooxygenase (hog, rat), 497
 Veratridine, calcium-mediated neuronal death, protection by flunarizine, brain neuronal cultures (rat), 525
 Vesamicol, receptor occupancy, acetylcholine active transport inhibition, synaptic vesicles (*Torpedo*), 452
 Vesicular uptake system, cation lucigenin, hepatocytes (rat), 537
 Vinblastine, binding to stabilized microtubules, 366
 Vincristine, 1- β -D-arabinofuranosylcytosine enhancement, resistance, mammalian tissue culture cells, 360
 Voltage clamp, activation of glycine coagonist site, NMDA receptors, oocytes (*Xenopus*), 556
 VP-16, podophyllotoxin analogs, tubulin polymerization, DNA topoisomerase II (human), 78

**Copyright © 1989 by the American Society for
Pharmacology and Experimental Therapeutics**

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. William A. Catterall, Editor, *Molecular Pharmacology*, Department of Pharmacology, SJ-30, University of Washington, Seattle, Washington 98195, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. If the submitted manuscript utilizes or makes bibliographic reference to articles in press, copies should be included with the manuscript. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text,

including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baue, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brian. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7) Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, a, b, c, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers after such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (\times , \circ , \bullet , \square , \blacksquare , \triangle , \blacktriangle , \odot). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.

Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
1968 Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
1971 Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
1975 George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
1978 Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
1983 Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.

INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

Correspondence concerning business matters should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202-3993 U.S.A.

Correspondence regarding editorial matters should be addressed to the Editor, Dr. William A. Catterall, Department of Pharmacology, SJ-30, University of Washington, Seattle, WA 98195.

Annual Subscription Rates—U. S. A. AND POSSESSIONS: personal, \$80.00; institutional, \$185.00, single copy, \$17.00. FOREIGN: personal, \$110.00; institutional, \$210.00; single copy, \$20.00. JAPAN: personal, \$151.00; institutional, \$251.00 (includes air freight). (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost.

Japanese Yen price is available from our sole agent: USACO Corporation, 13-12 Shimbashi 1-Chome, Minato-Ku, Tokyo 105, Japan, telephone 03-502-6471.

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

New subscriptions and renewals are entered to begin with the January or July issue.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Reprints of individual articles are available *only* from authors.

Microfilm. For availability, inquire of Williams & Wilkins.

Williams & Wilkins, Baltimore, MD. 21202-3993 U. S. A.